UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Start-Up Raises $17.5m In Series A
Executive Summary
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
You may also be interested in...
Interview: Achilles Advances Armed With £100m
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.